Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9181)
All Articles published online
|
Publishing Process of This Article
|
Nov 15, 2021 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832 [PMID: 34853653 DOI: 10.4251/wjgo.v13.i11.1813] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v13/i11/1813.htm |
| Number | Citing Articles |
| 1 |
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.980214
|
| 2 |
Zaiba S. Dawood, Zachary J. Brown, Laura Alaimo, Henrique A. Lima, Chanza Shaikh, Erryk S. Katayama, Muhammad M. Munir, Zorays Moazzam, Yutaka Endo, Selamawit Woldesenbet, Timothy M. Pawlik. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis. HPB 2024; 26(5): 618 doi: 10.1016/j.hpb.2024.02.003
|
| 3 |
Endrit Shahini, Giuseppe Pasculli, Antonio Giovanni Solimando, Claudio Tiribelli, Raffaele Cozzolongo, Gianluigi Giannelli. Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. International Journal of Molecular Sciences 2023; 24(5): 4286 doi: 10.3390/ijms24054286
|
| 4 |
Anne Olbrich, Johannes Niemeyer, Hendrik Seiffert, Sebastian Ebel, Olga Gros, Florian Lordick, Dirk Forstmeyer, Daniel Seehofer, Sebastian Rademacher, Timm Denecke, Madlen Matz-Soja, Thomas Berg, Florian van Bömmel. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2024; 150(2) doi: 10.1007/s00432-023-05526-z
|
| 5 |
Jiang Zhonghao, Yang Fan. New advances in the treatment of intermediate and advanced hepatocellular carcinoma. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1430991
|
| 6 |
Lauren Matevish, Madhukar S. Patel, Parsia A. Vagefi. Downstaging Techniques for Hepatocellular Carcinoma in Candidates Awaiting Liver Transplantation. Surgical Clinics of North America 2024; 104(1): 145 doi: 10.1016/j.suc.2023.07.004
|
| 7 |
Huilin Xu, Dedong Cao, Dingjie Zhou, Nan Zhao, Xixian Tang, Vishalkumar G. Shelat, Hrishikesh Samant, Sanjaya K. Satapathy, Francisco Tustumi, Giuseppe Aprile, Anbing He, Ximing Xu, Wei Ge. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11488-9
|
| 8 |
Ihtzaz Ahmed Malik, Mansi Rajput, Rieke Werner, Dorothea Fey, Niloofar Salehzadeh, Christine A. F. von Arnim, Jörg Wilting. Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-10247-6
|
| 9 |
Ruoning Yang, Yueyi Li, Hang Wang, Taolin Qin, Xiaomeng Yin, Xuelei Ma. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Molecular Biomedicine 2022; 3(1) doi: 10.1186/s43556-022-00071-6
|
| 10 |
Chia-Ying Hou, Chung-Yung Ma, Yu-Ju Lin, Chou-Long Huang, Horng-Dar Wang, Chiou-Hwa Yuh. WNK1–OSR1 Signaling Regulates Angiogenesis-Mediated Metastasis towards Developing a Combinatorial Anti-Cancer Strategy. International Journal of Molecular Sciences 2022; 23(20): 12100 doi: 10.3390/ijms232012100
|
| 11 |
Khadijeh Mahboobnia, Dianne J. Beveridge, George C. Yeoh, Tasnuva D. Kabir, Peter J. Leedman. MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities. International Journal of Molecular Sciences 2024; 25(17): 9393 doi: 10.3390/ijms25179393
|
| 12 |
Shijia Lu, Chenxiao Zhang, Jinglong Wang, Limei Zhao, Guofei Li. Research progress in nano-drug delivery systems based on the characteristics of the liver cancer microenvironment. Biomedicine & Pharmacotherapy 2024; 170: 116059 doi: 10.1016/j.biopha.2023.116059
|